LCTX: Lineage Bio Stock Price

Lineage Cell Therapeutics (LCTX) operations are shielded from political turmoil due to the medical status of its projects and partnerships across Europe and the US. Meanwhile, financial stability relies on external funding, and revenue stands at 1.12, as stable income is currently absent. This price chart, serving as the primary valuation tool, complements data regarding the company's proprietary R&D centers and sterile manufacturing plant in Israel.

lineagecell.com - LCTX Price (period 07/04/2022 - 11/12/2026)

Analytical breakdowns and data insights for company Lineage Cell Therapeutics Inc (LCTX)

- stock value and consensus price forecast:

Price Chart Lineage Cell Therapeutics|LCTX - Price Target Chart

- market capitalization information:

Market Capitalization Lineage Cell Therapeutics Inc|LCTX - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value per Share Lineage Cell Therapeutics|LCTX - Total Net Assets|Market Cap to Net Assets Ratio lineagecell.com|LCTX - Total Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

LCTX - Net Income|Projected Future Earnings Lineage Cell Therapeutics|LCTX - Market Cap to Earnings|Future Price to Earnings Lineage Cell Therapeutics, Inc.|LCTX - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lineage Cell Therapeutics Inc|LCTX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Lineage Cell Therapeutics|LCTX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months lineagecell.com|LCTX - Earnings per share growth in current year|Earnings growth forecast for next year Lineage Cell Therapeutics

Summary company analysis:Lineage Cell Therapeutics

The price reflects the current market value of Lineage Cell Therapeutics (LCTX) equity, instantly integrating all available data on the enterprise's potential into the quotes. By analyzing historical price action, investors assess the probability of commercial success for the company's regenerative technologies aimed at restoring spinal cord and vision functions, determining a fair balance between high innovation risks and future asset capitalization.

Competitors of Lineage Cell Therapeutics (LCTX)